Merck & Co buys cancer biotech VelosBio for $2.75bnMerck & Co has agreed to buy California biotech VelosBio and its experimental cancer drug for $2.75 billion Share XMerck & Co buys cancer biotech VelosBio for $2.75bnhttps://pharmaphorum.com/news/merck-co-buys-cancer-biotech-velosbio-for-2-75bn/
ANGLE raises £20m, eyes opportunity in immunotherapy trialsLiquid biopsy company ANGLE has raised £20m through a conditional placing on the London Stock Exchange which will Share XANGLE raises £20m, eyes opportunity in immunotherapy trialshttps://pharmaphorum.com/news/angle-raises-20m-eyes-opportunity-for-parsortix-in-immunotherapy-trials/
Toxic positivity and grief: The reality of living through cancerCancer doesn’t end when treatment stops – it’s a lifelong journey and people need support throughout, says patient Share XToxic positivity and grief: The reality of living through cancerhttps://pharmaphorum.com/views-analysis-patients/toxic-positivity-and-grief-the-reality-of-living-through-cancer/
Ibrance trial failure dashes Pfizer’s growth hopes for the drugPfizer already makes big revenues from its breast cancer drug Ibrance, but a late-stage trial failure has set Share XIbrance trial failure dashes Pfizer’s growth hopes for the drughttps://pharmaphorum.com/news/ibrance-trial-failure-dashes-pfizers-growth-hopes-for-the-drug/
Immunomedics wows ESMO with breast cancer data revealImmunomedics has revealed the trial data that convinced Gilead to stage a $21 billion takeover, after the biotech’s Share XImmunomedics wows ESMO with breast cancer data revealhttps://pharmaphorum.com/news/immunomedics-wows-esmo-with-breast-cancer-data-reveal/
Giving the forgotten generation of cancer patients a voiceYoung people with cancer need a “seat at the table”, but instead they are often side-lined and voiceless. Share XGiving the forgotten generation of cancer patients a voicehttps://pharmaphorum.com/views-analysis-patients/giving-the-forgotten-generation-of-cancer-patients-a-voice/
Merck & Co signs multi-billion cancer drug development deal with Seattle GeneticsMerck & Co has signed a multi-billion cancer drug development deal, which will see it investing $1 billion Share XMerck & Co signs multi-billion cancer drug development deal with Seattle Geneticshttps://pharmaphorum.com/news/merck-co-signs/
UK medical journals spar over breast cancer screening studyScreening women for breast cancer in their 40s rather than their 50s could save lives, say the authors Share XUK medical journals spar over breast cancer screening studyhttps://pharmaphorum.com/news/uk-medical-journals-spar-over-breast-cancer-screening-study/
AstraZeneca inks $6bn cancer drug deal with Daiichi SankyoAstraZeneca has begun a new agreement with Daiichi Sankyo to develop and market an antibody to treat cancer, Share XAstraZeneca inks $6bn cancer drug deal with Daiichi Sankyohttps://pharmaphorum.com/news/astrazeneca-inks-6bn-cancer-drug-deal-with-daiichi-sankyo/
